Printer Friendly

Australia : Transcript of doorstop in Melbourne.

To our patients - patients such as Ben and Christine and Denise and all the other patients who have inspiring stories; that their lives faced the most immense of challenges and yet through their determination, the support of the patient groups such as Ovarian Cancer Australia, the Leukaemia Foundation, the amazing Unicorn Foundation, and all of the different groups.

And then the incredible new pharmaceuticals which are coming through whether they are in particular immunotherapies or new breakthrough drugs, or combination immunotherapies.

And then of course above all else, our incredible clinicians - clinicians such as Professor David Ritchie, of Dr Sandhu and so many others who save lives and protect lives and inspire us.

We were able to visit some of our researchers upstairs who were looking for new genetic pathways in order to identify the source and therefore the response to dealing with cancers such as those that were looking at today.

Today, I am delighted to be able to announce that the Australian Government will list five new medicines on the Pharmaceutical Benefits Scheme to help save and protect the lives of patients struggling with different cancers.

Over 2900 patients with five different types of cancers will benefit from these new listings on the PBS. Cancers such as acute myeloid leukaemia, advanced melanoma - stage 3 and stage 4 melanoma; bowel cancer; neuroendocrine tumours for the intestines and the pancreas; and also the insidious ovarian cancer will all benefit from these new medicines.

In particular, we'll be announcing and listing on the Pharmaceutical Benefits Scheme as of tomorrow Rydapt for acute myeloid leukaemia - this will help 200 patients and would otherwise have cost up to $30,000 a year.

Somatuline Autogel which is for neuroendocrine tumours of the gastroentero and pancreatic condition. So in other words intestinal and pancreatic cancers will have a new treatment and this will help 760 patients and would otherwise have cost $23,000 a year.

The combination immunotherapy breakthrough that help Jarryd Roughead OPDIVO and Yervoy - this would otherwise have cost $100,000 a year for patients.

And for melanoma this will help approximately 800 Australian patients a year. Lonsurf for bowel cancer - over 885 patients will benefit and this would have cost $6000. And then LYNPARZA for ovarian cancer and more than 220 patients will benefit and it would have cost $90,000.

These are the things you can only do if you have a strong economy. It's absolutely fundamental to be able to have that basis to list these medicines but even more importantly, it's a privilege to be able to deliver what the medical experts have recommended and if they recommend it, we will list it.

But to meet our researchers, to meet our extraordinary pharmaceutical leaders, to meet the medical communities that are supporting and then above all else to meet the patients who are benefiting is to see the very best of medicine and the very best of Australia here in the very best of treatment houses anywhere in the world.

[c] 2018 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2018 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:8AUST
Date:Dec 8, 2018
Previous Article:Australia : $100 million investment in new PBS listings to fight cancer.
Next Article:Australia : Medicines for severe asthma and growth hormone deficiency listed on the PBS.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters